First Author: T.Georgiou CYPRUS
Co Author(s): D. Nicolaou A. Neokleous P. Kolovos S. Michael C. Ikonomu 0 0 0 0 0 0 0 0 0
Back to previous
A pilot study to evaluate the importance of the arachidonic acid/eicosapentaenoic acid (AA/EPA) blood ratio when treating dry age-related macular degeneration (AMD) and macular dystrophies (MD) with high doses of omega-3 fatty acids.
Ophthalmos Research and Educational Institute, Cyprus
Twenty-six patients (32 eyes) with dry AMD and 9 patients (16 eyes) with MD were treated with 5-10 grams of EPA/DHA at a ratio of 2:1. Visual acuity using the EDTRS chart was noted and a blood test with a finger stick for AA/EPA analysis was performed using a gas chromatography equipment.
The gain of letters when taking 5 grams of omega-3 fatty acids was 10.6 lines and when taking 8-10 grams was 12.85 letters (p<0.05). The gain of letters when the AA/EPA ratio was between 1 and 1.5 was 15.7 letters (p<0.05), when the ratio was between 1.5 and 2 patients gained 11.1 letters and when it was > 2 patients gained 8.0 letters.
The blood ratio of AA/EPA plays a major role for improving vision in patients with dry AMD and MD. The dose of omega-3 fatty acids when treating patients with dry AMD and MD should be adjusted so that the AA/EPA ratio is between 1 and 1.5 for maximum visual gain.